

Additional file 2: Efficacy outcomes, withdrawals and adverse events

Sildenafil trials

Study	Dose and number of patients	Doses taken median (range)	Taking max dose at endpoint (n)	Improved erections GAQ1 (n)	Mean number of erections per week (grade 3/4)	Successful attempts at SI (mean per patient, %) SEP	More than 60% attempts successful (n)	More than 40%	Final score (SD) IIEFQ3
Boolell et al. 1996	placebo, n=12	7/wk	n/a	2/12	1.3 (0.5-2.7)	no data	no data	no data	no data
	25 mg, n=12	7		10/12	6.1 (3.2-11.4)				
Padma-Nathan et al. 1998	placebo, n=166	29/12 wk	158/166	23/118	no data	20	(75%) 21/138	no data	2.3 (0.1)
	25-100 mg, n=163	32	121/163	101/136		65	81/137		3.9 (0.1)
Goldstein et al. 1998	placebo, n=216	no data	n/a	54/216	0.8	no data	no data	no data	2.2 (0.2)
	25 mg, n=102			57/102	1.1				3.2 (0.2)
	50 mg, n=107			82/107	1.7				3.5 (0.2)
	100 mg, n=107			90/107	1.6				4.0 (0.2)
Derry et al. 1998	placebo, n=13	8/4 wk	n/a	1/13	0.4	15	no data	no data	no data
	50 mg, n=12	8		9/12	1.8	30			
Giuliano et al. 1999	placebo, n=174	7/6 wk	no data	7/168	no data	0	6/174	no data	2.2
	25-100 mg, n=175	10	102/175	127/168		55	73/175		3.8
Dinsmore et al. 1999	placebo, n=54	1.7/wk	no data	10/54	0.6	30	no data	no data	1.7
	25-100 mg, n=57	2.1	79% on 50/100	46/57	1.7	73			3.6
Montorsi et al. 1999	placebo, n=127	20-30 across groups/12 wks	n/a	27/114	no data	24	no data	no data	2.2
	25 mg, n=128			80/119		64			3.2
	50 mg, n=132			95/122		73			3.7
	100 mg, n=127			101/118		73			3.8
Rendell et al. 1999	placebo, n=132	25 (2-83)/12 wk	127/132	13/127	no data	no data	no data	no data	2.0
	25-100 mg, n=136	31 (3-81)	126/136	74/131					3.2
Tan et al. 2000	placebo, n=127		no data	40/121	no data	30	no data	no data	2.6
	25-100 mg, n=127		81/125	109/125		78			4.2

Sildenafil trials						Withdrawals			Adverse events			
Mean (SD) change EFQ3	Final score (SD) IIEFQ4	Mean (SD) change EFQ4	Final score (SD) EF Domain	Mean (SD) change EF Domain	Normal EF score (26-30) at endpoint (n)	Total	Lack of Efficacy	Adverse events	All cause	Severe	Serious	Treatment related
no data	no data	no data	no data	no data	no data	0/12	0/12	0/12	5/12	0/12	0/12	no data
0.2	1.8 (0.1)	0.2	12.2	0.2	no data	0/12	0/12	0/12	6/12	1/12	0/12	no data
1.9	3.6 (0.1)	2.1	22.1	11		13/166	3/166	1/166	no data	no data	no data	no data
						9/163	1/163	1/163				
0.1	2.1 (0.2)	0.4	no data	no data	no data	36/216	11/216	1/216	no data	no data	no data	no data
1.2	3.1 (0.2)	1.7				15/102	3/102	1/102				
1.6	3.5 (0.2)	2.0				8/107	2/107	1/107				
2.0	3.9 (0.2)	2.2				8/107	0/107	2/107				
no data	no data	no data	no data	no data	no data	1/14	0/14	0/14	4/13	no data	1/13	1/13
						0/13	0/13	0/13	5/12		0/12	2/12
0.2	1.7	0.1	no data	no data	no data	4/174	0/174	2/174	no data	no data	no data	1/174
2.9	3.6	2.1				6/175	0/175	5/175				3/175
0.03	1.6	0.08	10.1	-0.2	no data	11/54	1/54	0/54	no data	14 total	no data	no data
1.9	3.7	2.1	21.5	11.2		3/57	1/57	0/57				
-0.03	2.0	0.1	no data	no data	no data	no data	no data	1/127	42/127	no data	7 total	11/127
1.0	3.0	1.2						0/128	63/128	1/128		39/128
1.5	3.4	1.6						1/132	80/132	2/132		50/132
1.6	3.6	1.8						5/127	92/127	5/127		72/127
0.4	1.6	0.2	10.4	1.2	no data	11/132	1/132	1/132	no data	no data	no data	1/132
1.4	2.9	1.4	17.5	7.4		5/136	1/136	1/136				22/136
0.3	2.4	0.5	15.5	2.2	no data	11 total	4/127	0/127	29/127	4 total	1/127	13/127
2.0	4.2	2.2	25.1	11.8			0/127	1/127	42/127		1/127	29/127

Olsson et al. 2000	placebo, n=95	no data	no data	35/91	2.1	no data	no data	no data	2.4
	10 mg, n=90			54/84	2.8				2.9
	25 mg, n=85			65/82	3.0				3.0
	50 mg, n=81			67/76	3.6				3.3
Palmer et al. 2000	placebo, n=17	5 x 2	n/a	2/15	no data	no data	no data	no data	no data
	25 mg, n=17	5		12/15					
	50 mg, n=17	5							
Chen et al. 2001	placebo, n=113	41/12 wk	106/113	43/113	no data	30	no data	no data	3.0
	25-100 mg, n=111	35	79/111	98/111		62			4.2
Boulton et al. 2001	placebo, n=109	10.4 ±6/4 wk	no data	11/103	no data	14.4 (8-23)	no data	no data	1.9 (0.2)
	25-100 mg, n=110	10.9 ±6	85/110	66/102		58.8 (48-69)			3.4 (0.2)
Meuleman et al. 2001	placebo, n=156	34 (3-	no data	36/159	1.3	no data	no data	no data	2.2 (0.2)
	25-100 mg, n=159	162)/26 wk 49 (3-181)	78/159	126/159	3.2				3.7 (0.1)
Eardley et al. 2001	placebo, n=44	2.6 (0.3)/wk	no data	9/36	1.4	no data	no data	no data	no data
	25-100 mg, n=44	3.4 (0.3)		34/36	4.2				
Lewis et al. 2001	placebo, n=123	34/12 wk	118/123	21/123	no data	no data	no data	no data	2.2
	25-100 mg, n=124	33	101/124	87/124					3.7
Seidman et al. 2001	placebo, n=78	3.0/wk	73/75	8/70	no data	no data	no data	no data	2.2 (0.2)
	25-100 mg, n=74	3.6	57/72	60/66					3.7 (0.3)
Incrocci et al. 2001	placebo, n=60	no data	no data	5/60	no data	18	no data	no data	1.6 (1.1)
	25-100 mg, n=60		54/60	27/60		55			2.8 (1.7)
Seibel et al. 2002	placebo, n=24	no data	n/a	2/21	no data	no data	no data	no data	2.8 (0.8)
	50 mg, n=21			17/20					4.0 (1.1)
Becher et al. 2002	placebo, n=71	31 (1-83)	57/69	22/65	no data	26.5	no data	no data	2.7 (0.2)
	25-100 mg, n=72	33 (1-80)	36/71	51/66		62.5			3.8 (0.2)
Young et al. 2002 Blacks 1st 6-wk period	placebo, n=122	no data	no data	41/114	no data	no data	no data	no data	3.1
	25-100 mg, n=124			93/118					4.1
Young et al. 2002 Hisp 1st 6-wk period	placebo, n=98	no data	no data	26/89	no data	no data	no data	no data	3.0
	25-100 mg, n=99			73/89					4.0
Glina et al. 2002	placebo, n=121	32	no data	no data	no data	no data	no data	no data	2.6 (0.2)
	25-100 mg, n=124	36	71/124						3.9 (0.2)

0.4	2.1	0.6	no data	no data	no data	9/95	0/95	4/95	no data	no data	3 total	no data
0.9	2.6	1.1				7/90	1/90	2/90				
1.0	2.8	1.3				7/85	2/85	4/85				
1.3	3.2	1.7				11/81	1/81	7/81				
no data	no data	no data	no data	no data	no data	2/17	0/17	0/17	no data	no data	no data	no data
						2/17	0/17	0/17	sild doses combined			
0.7	2.9	0.9	18.1	4.5	no data	6/117	1/117	1/117	58/117	no data	4/117	22/117
1.9	4.1	2.1	24.3	11.7		10/119	1/119	1/119	76/119	1/119	4/119	52/119
0.1	1.8 (0.2)	0.4	11.5 (1.2)	1.1	no data	no data	no data	2/109	no data	no data	no data	7/109
1.7	3.4 (0.2)	2.9	20.4 (1.2)	10.0				2/110				41/110
0.6	2.1 (0.2)	0.5	13.3 (0.7)	1.5	no data	77/156	54/156	1/156	no data	no data	6/156	no data
1.7	3.6 (0.2)	1.7	21.9 (0.7)	10.9		35/159	13/159	5/159			8/159	
no data	no data	no data	no data	no data	no data	5 total	0/44	1/44	14/43	no data	0/43	no data
							0/44	0/44	23/43		2/43	
0.5	1.9	0.5	no data	no data	no data	12/123	8/123	0/123	no data	0/123	3/123	20/123
2.0	3.5	2.1				7/124	2/124	2/124		1/124	3/124	52/124
0.6	2.0 (0.2)	0.6	12.4	3.1	no data	no data	no data	no data	no data	5 total	no data	10/78
2.1	3.9 (0.3)	2.5	23.4	14.1								35/74
0.1	1.5 (1.0)	0.2	10.6	0.9	no data	0/60	0/60	0/60	no data	0/60	no data	no data
1.3	2.6 (1.7)	1.3	16.9	7.2		0/60	0/61	0/62		0/60		
0.1	2.4 (0.9)	-0.1	15.2	-0.2	0/24	3/24	0/24	2/24	5/24	1/24	2/24	no data
1.2	3.7 (1.3)	1.3	23.0	7.0	7/21	1/21	0/21	0/21	3/21	0/21	0/21	
0.4	2.5 (0.2)	0.4	15.9 (0.7)	1.34	no data	6/71	0/71	1/71	21/71	1/21	1/71	no data
1.5	3.6 (0.2)	1.6	20.5 (0.6)	6.0		7/72	0/72	2/72	43/72	2/43	2/72	
0.5	2.9	0.6	17.6	3.5	no data	10/122	no data	no data	no data	no data	no data	4/122
1.5	3.9	1.7	23.3	9.2		6/123						22/124
0.6	2.6	0.5	16.4	2.9	no data	9/98	no data	no data	no data	no data	no data	11/97
1.6	3.8	1.7	23.2	9.7		13/99						26/98
0.5	2.3 (0.2)	0.6	no data	no data	no data	16/121	3/121	0/121	no data	no data	no data	no data
1.9	3.8 (0.2)	2.1				15/124	3/124	1/124				

Gomez et al. 2002	placebo, n=82 25-100 mg, n=76	no data	no data	38/82 59/72	no data	35 65	no data	no data	3.3 4.0
Lindsey et al. 2002	placebo, n=18 25-100 mg, n=14	no data	no data	3/18 11/14	no data	no data	no data	no data	no data
Nurnberg et al. 2003	placebo, n=41 25-100 mg, n=43	4.5 (2.1)/wk 5.3 (2.2)	30/35 32/41	no data	no data	no data	no data	no data	3.1 (1.6) 4.4 (1.1)
Padma-Nathan et al. 2003	placebo, n=113 100 mg, n=115	no data	n/a	no data	no data	no data	no data	no data	no data
Kongkanand et al. 2003	placebo, n=62 25-100 mg, n=63	no data	no data	no data	no data	no data	no data	no data	2.8 3.8
Levinson et al. 2003	placebo, n=126 25-100 mg, n=128	33/12 wk 41	114/126 86/128	33/122 93/126	no data	28 69	no data	no data	2.5 3.9
Stuckey et al. 2003	placebo, n=93 25-100 mg, n=95	10.6/month 11.4	no data 68/95	split by severity	no data	38 65	no data	no data	2.7 (0.5) 3.6 (0.5)
Choi et al. 2003	placebo, n=67 25-100 mg, n=66	22/8 wk 24.5	65/65 43/66	18/65 54/66	no data	25.9 62.0	no data	no data	2.7 4.2
Tignol et al. 2004	placebo, n=85 25-100 mg, n=83	21 (1-84) 31 (1-83)	72/85 42/83	28/85 68/83	no data	29 74	no data	no data	2.6 3.8
Safarinejad et al. 2004	placebo, n=138 100 mg, n=144	40 (4-97)/16 wk	n/a	14/128 68/134	no data	no data	no data	no data	2.2 (0.2) 2.8 (0.2)
DeBusk et al. 2004	placebo, n=76 25-100 mg, n=174	42 (5-102) 8 (1-40) 12 (1-36)	63/76 55/74	20/72 41/70	no data	25 51	no data	no data	2.7 3.5
Mahon et al. 2005	placebo, n=13 50-100 mg, n=13	no data	step inc 13/13 18/13	4/13 10/13	no data	no data	no data	no data	1.7 3.4
Fowler et al. 2005	placebo, n=113 25-100 mg, n=104	no data	108/113 67/104	27/113 94/104	no data	no data	no data	no data	2.4 (0.2) 4.0 (0.2)

0.9	2.9	0.9	18.4	4.8	no data	10/82	1/82	0/82	27/82	no data	0/82	18/82
1.6	3.8	1.8	22.1	8.5		12/76	0/76	1/76	39/76		0/76	33/76
no data	no data	no data	10.6	3.3	no data	0/18	0/18	0/18	4/18	0/18	0/18	no data
			23.6	13.1		0/14	0/14	0/14	7/14	1/14	0/14	
0	2.7 (1.6)	0.1	17.1 (8.1)	0.8	no data	6/41	5/41	1/41	no data	no data	no T-R	no data
1.3	4.2 (1.2)	1.3	27.1 (3.7)	9.3		1/43	0/43	1/43				
no data	no data	no data	no data	no data	no data	5/115	20/113	0/113	15/113	no data	no data	no data
						4/113	0/115	2/115	29/115			
0.8	2.5	0.7	15.9	3.0	no data	1/62	0/62	0/62	21/62	no data	no data	7/62
1.6	3.6	1.6	21.8	8.9		0/63	0/63	0/63	23/63		0/63	19/63
0.4	2.2	0.5	no data	no data	no data	11/126	4/126	0/126	43/126	no data	0/126	20/126
1.8	3.7	2.0				15/128	0/128	3/128	63/128		3/128	50/128
0.5	2.2 (0.5)	0.5	14.5	2.5	no data	16/93	3/93	3/93	13/93	1/93	1/93	no data
1.0	3.3 (0.5)	1.4	20	6		10/95	2/95	2/95	34/95	5/95	0/95	
0.1	2.1	0.3	14.5	1.5	no data	4/67	1/67	0/67	25/67	0/67	2/67	14/67
1.6	3.7	2.0	23.4	10.4		0/66	0/66	0/66	46/66	1/66	0/66	37/66
no data	2.1	no data	14	no data	no data	10/85	4/85	0/85	14/85	no data	no data	no data
	3.5		24			9/83	1/83	3/83	34/83			
0.4	2.0 (0.2)	0.3	11.4	1.3	no data	10/138	3/138	no data	no data	no data	no data	2/138
1.0	2.9 (0.2)	1.2	16.8	6.3		10/144	1/144	8/144				32/144
0.8	2.3	0.7	15.0	4.5	no data	15/76	4/76	2/76	24/76	no data	2/76	no data
1.6	3.3	1.7	19.8	9.3		10/74	0/74	3/74	35/74		1/74	
no data	1.6	no data	12	5.3	no data	0/13	0/13	0/13	0/13	0/13	0/13	0/13
	3.2		20	13.3		0/13	0/13	0/13	1/13	0/13	0/13	1/13
0.5	2.0 (0.2)	0.5	no data	no data	no data	25/113	24/113	1/113	49/113	4/113	3/113	7/113
2.1	3.9 (0.2)	2.4				2/104	0/104	0/104	68/104	10/104	3/104	44/104

Tadalafil trials

Study	Dose and number of patients	Doses taken median (range)	Taking max dose at endpoint (n)	Improved erections GAQ1 (n)	Mean number of erections per week (grade 3/4)	Successful attempts at SI (mean per patient, %) SEP	More than 60% attempts successful (n)	More than 40%	Final score (SD) IIEFQ3
Padma-Nathan et al. 2001	placebo, n=35	max 14	n/a	6/35	no data	26.6	no data	no data	2.5 (0.3)
	2 mg, n=35			18/35		45.7			3.5 (0.3)
	5 mg, n=37			22/37		61.7			4.2 (0.2)
	10 mg, n=36			29/36		69.8			4.1 (0.2)
	25 mg, n=36			29/36		70.2			4.2 (0.2)
Saenz de Tejada et al. 2002	placebo, n=71	no data	n/a	18/71	no data	no data	no data	no data	
	10 mg, n=73			41/73					
	20 mg, n=72			46/72					
Porst et al. 2003	placebo, n=173	2+2	n/a	no data	no data	no data	no data	no data	no data
	20 mg, n=175	2+2							
Eardley et al. 2004	placebo, n=52	no data	n/a	12/52	no data	29.9	no data	no data	2.5 (1.7)
	20 mg, n=168			138/168		73.9			4.3 (1.4)
Skoumal et al. 2004	placebo, n=102	2.9/wk	n/a	34/102	no data	34	no data	no data	no data
	20 mg, n=301	3.9/wk		259/301		73			
Seftel et al. 2004	placebo, n=48	no data	n/a	9/48	no data	22.6	no data	no data	no data
	20 mg, n=159			125/159		64.2			
Montorsi et al. 2004	placebo, n=102	2.1±1.4	n/a	23/102	no data	19.4	no data	no data	no data
	20 mg, n=201	2.3±1.5		124/201		40.5			
Carson et al. 2005	placebo, n=49	no data	n/a	7/49	no data	25.0	no data	no data	2.4
	20 mg, n=146			107/146		50.3			3.3

Tadalafil trials

Mean (SD) change EFQ3	Final score (SD) IIEFQ4	Mean (SD) change EFQ4	Final score (SD) EF Domain	Mean (SD) change EF Domain	Normal EF score (26-30) at endpoint (n)	Withdrawals			Adverse events			
						Total	Lack of Efficacy	Adverse events	All cause	Severe	Serious	Treatment related
-0.3 (0.2)	2.4 (0.3)	0.2 (0.2)	14.7 (1.2)	1.0 (0.9)	no data	7 total	0/35	0/35	3/35	no data	0/35	3/35
0.6 (0.2)	3.1 (0.3)	0.8 (0.2)	19.3 (1.5)	4.1 (1.1)			0/35	0/35	6/35		1/35	6/35
1.2 (0.2)	3.7 (0.2)	1.4 (0.2)	22.9 (1.0)	7.3 (1.0)			0/37	0/37	no data		0/37	no data
1.0 (0.2)	4.0 (0.2)	1.7 (0.2)	23.6 (1.1)	7.8 (1.2)			0/36	2/36	no data		0/36	no data
1.3 (0.2)	4.0 (0.2)	1.7 (0.2)	24.2 (1.2)	9.4 (1.2)			0/36	0/36	13/36		1/36	13/36
no data		no data		0.1	no data	25 total	0/71	1/71	22/71	no data	1/71	no data
				6.4			3/73	1/73	29/73		0/73	
				7.3			2/72	4/72	32/72		1/72	
no data	no data	no data	no data	no data	no data	no data	no data	no data	no data	no data	no data	no data
0.1 (1.4)	2.1 (1.5)	0.1 (1.3)	13.8 (8.5)	0.4 (6.6)	9/52	9/52	no data	1/52	no data	no data	1/52	no data
1.9 (1.7)	4.1 (1.5)	2.2 (1.7)	24.5 (7.5)	11.1 (27.2)	114/168	16/168		5/168			3/168	
no data	no data	no data	17.4 (15.9- 18.9)	1.4 (0.8-2.1)	16/97	8/104	5/104	0/104	no data	no data	0/104	no data
				9.8 (9.0- 10.6)	188/292	15/305	0/305	1/305			2/305	
no data	no data	no data	13.6	0.3 (0.9)	4/48	8/48	5/48	1/48	no data	no data	0/48	no data
				22.5	80/159	23/159	3/159	8/159			2/159	
no data	no data	no data	13.3	1.1 (0.6)	5/102	26/102	10/102	2/102	27/102	3/102	0/102	no data
				17.7	48/201	40/201	16/201	11/201	104/201	10/201	0/201	
0.1 (0.27)	2.0	0 (0.22)	13.5	-0.2 (1.08)	no data	18/49	9/49	1/49	no data	no data	1/49	no data
1.1 (0.15)	3.1	1.3 (0.15)	19.5	6.9 (0.75)		30/146	8/146	8/146			3/146	

Vardenafil trials

Study	Dose and number of patients	Doses taken median (range)	Taking max dose at endpoint (n)	Improved erections GAQ1 (n)	Mean number of erections per week (grade 3/4)	Successful attempts at SI (mean per patient, % SEP)	More than 60% attempts successful (n)	More than 40%	Final score (SD) IIEFQ3
Porst et al. 2001	placebo, n=147	26/12 wks	n/a	44/147	no data	39.5	40/147	no data	2.7 (1.5)
	5 mg, n=146	29		96/146		71.1	90/146		3.7 (1.5)
	10 mg, n=140	29		106/140		70.9	80/140		3.9 (1.5)
	20 mg, n=147	31		118/147		74.6	96/147		4.0 (1.4)
Hellstrom et al. 2002	placebo, n=197	no data	n/a	45/197	no data	32.7	no data	no data	no data
	5 mg, n=205			115/205		51.7			
	10 mg, n=206			158/206		64.7			
	20 mg, n=197			159/197		66.7			
Goldstein et al. 2003	placebo, n=140	1.8/wk	n/a	17/140	no data	23	split by baseline severity	no data	no data
	10 mg, n=149	2.1		78/149		49			
	20 mg, n=141	2.0		94/141		54			
Brock et al. 2003	placebo, n=137	no data	n/a	12/137	no data	10	no data	no data	no data
	10 mg, n=139			78/139		37			
	20 mg, n=147			87/147		34			
Hatzichristou et al. 200	placebo, n=154	20/12 wks	140/155	55/154	no data	30	no data	no data	no data
	5-20 mg, n=155	30	110/154	133/155		69			
Carson et al. 2004	placebo, n=221	8.4-9.2/4	no data	32/221	no data	19.9	no data	no data	no data
	5-20 mg, n=227	wks	189/227	140/227		50.8			
Nagao et al. 2004	placebo, n=71	10.1-11.5	n/a	25/71	no data	33.4	no data	no data	3.2
	5 mg, n=67	no data		49/67		63.5			4.0
	10 mg, n=75			64/75		78.5			4.5
	20 mg, n=66			57/66		79.3			4.6

Vardenafil trials

Mean (SD) change EFQ3	Final score (SD) IIEFQ4	Mean (SD) change EFQ4	Final score (SD) EF Domain	Mean (SD) change EF Domain	Normal EF score (26-30) at endpoint (n)	Withdrawals		Adverse events				
						Total	Lack of Efficacy	Adverse events	All cause	Severe	Serious	Treatment related
0.2 (1.5)	2.5 (1.5)	0.5 (1.7)	15.6 (7.3)	1.6	no data	no data	no data	2/152	no data	no data	4/152	no data
1.2 (1.7)	3.5 (1.5)	1.4 (1.7)	20.9 (7.3)	5.7				7/147			4/147	
1.3 (1.5)	3.6 (1.5)	1.5 (1.6)	22.1 (7.5)	8.0				2/141			1/141	
1.5 (1.7)	3.8 (1.4)	1.7 (1.6)	22.8 (7.5)	9.0				1/150			2/150	
no data	no data	no data	14.8	1.2	split by baseline severity	106/197	39/177	4/182	no data	no data	9/182	13/182
			17.8	5.3		77/205	26/190	8/193			10/193	37/193
			21.2	7.8		55/206	10/196	7/199			6/199	66/199
			21.8	9.0		59/197	9/186	15/188			8/188	79/188
no data	no data	no data	12.6	no data	no data	no data	5/140	2/143	no data	no data	4/143	no data
			17.1				3/149	4/152			3/152	
			19.0				0/141	5/144			4/144	
no data	no data	no data	9.2	0.1	no data	48/145	27/137	1/140	no data	3/140	no data	no data
			15.3	6.0		32/146	8/139	5/140		7/140	3/140	
			15.3	6.1		30/149	14/147	5/147		5/147	no data	
no data	no data	no data	14.5	no data	no data	49/166	20/154	3/164	44/164	no data	5/164	8/164
			23.3			25/167	2/155	5/157			4/157	45/157
no data	no data	no data	10.5	0.8	12/205	42/233	17/226	3/226	no data	6/226	no data	no data
			17.6	8.3		26/230	5/231	5/231		5/231		
0.6	2.3	0.8	16.7	3.1	no data	19/72	5/71	4/71	37/71	no severe AEs	no SAEs	15/71
1.2	3.5	1.9	22.4	8.3		9/68	1/67	2/67	39/67			24/67
1.7	4.2	2.6	25.6	11.8		11/76	0/75	2/75	47/75			34/75
2.1	4.3	2.8	26.0	12.6		6/67	2/66	3/66	49/66			36/66